0.335
0.02 (4.79%)
| Previous Close | 0.320 |
| Open | 0.321 |
| Volume | 1,130,517 |
| Avg. Volume (3M) | 1,075,287 |
| Market Cap | 33,086,810 |
| Price / Sales | 24.34 |
| Price / Book | 4.49 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -443.03% |
| Diluted EPS (TTM) | -0.090 |
| Quarterly Revenue Growth (YOY) | 11.90% |
| Total Debt/Equity (MRQ) | 3.76% |
| Current Ratio (MRQ) | 1.28 |
| Operating Cash Flow (TTM) | -4.79 M |
| Levered Free Cash Flow (TTM) | -2.91 M |
| Return on Assets (TTM) | -49.91% |
| Return on Equity (TTM) | -104.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | IGC Pharma, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.13 |
|
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 9.16% |
| % Held by Institutions | 19.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dearborn Partners Llc | 31 Dec 2025 | 84,401 |
| Lawood & Co | 31 Mar 2026 | 75,000 |
| Truist Financial Corp | 31 Mar 2026 | 36,667 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |